Graft Versus Host Disease (GvHD) Treatment Global Market Report 2024

Description

Graft versus host disease (GVHD) treatment encompasses a range of medical interventions designed to manage or mitigate the complications stemming from GVHD, a condition wherein transplanted donor cells attack the recipient's tissues. These treatments are employed to address the ramifications of GVHD, a disease characterized by the recipient's tissues being targeted by transplanted donor cells.

The primary product types utilized in graft versus host disease (GVHD) treatment include corticosteroids, monoclonal antibodies, immunosuppressants, among others. Corticosteroids are a class of steroid hormones produced in the adrenal cortex of vertebrates, as well as synthetic analogues of these hormones. GVHD treatment addresses various disease types such as acute GVHD, prophylaxis GVHD, and chronic GVHD. These treatments are utilized by diverse end users including hospital pharmacies, retail pharmacies, and online pharmacies.

The graft versus host disease (GVHD) treatment market research report is one of a series of new reports from The Business Research Company that provides graft versus host disease (GVHD) treatment market statistics, including graft versus host disease (GVHD) treatment industry global market size, regional shares, competitors with a graft versus host disease (GVHD) treatment market share, detailed graft versus host disease (GVHD) treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the graft versus host disease (GVHD) treatment industry. This graft versus host disease (GVHD) treatment research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The graft versus host disease (GVHD) market size has grown strongly in recent years. It will grow from $2.65 billion in 2023 to $2.85 billion in 2024 at a compound annual growth rate (CAGR) of 7.5%. The growth observed during the historic period can be attributed to several factors, including an increase in the number of allogeneic transplantations, a growing incidence of acute GVHD, an increasing rate of hematopoietic stem cell treatments, rising demand for bone marrow transplants, the escalating prevalence of GVHD worldwide, a rise in chronic GVHD cases, advancements in technology, and an increase in the patient population.

The graft versus host disease (GVHD) market size is expected to see strong growth in the next few years. It will grow to $3.82 billion in 2028 at a compound annual growth rate (CAGR) of 7.6%. The anticipated growth in the forecast period can be attributed to several factors, including an increase in the number of allogeneic transplantations, a growing incidence of acute GVHD, an increasing rate of hematopoietic stem cell treatment, rising demand for bone marrow transplants, the rising prevalence of GVHD worldwide, an increase in chronic GVHD cases, advancements in technology, and a rise in the patient population. Major trends expected in the forecast period include partnerships, investments, product approvals, and customizations.

The anticipated rise in hematological disorders is expected to drive the growth of the graft versus host disease (GVHD) treatment market in the foreseeable future. Hematological disorders, which encompass various conditions affecting the blood and its components, are becoming more prevalent due to factors such as unhealthy lifestyle habits, genetic predisposition, and exposure to environmental toxins such as radiation, chemicals, and pollutants. Treatment strategies developed for managing GVHD can have broader implications for patients with hematological disorders, presenting new opportunities for immune modulation and improved disease management. For example, according to the Leukemia & Lymphoma Society's 2023 report, leukemia, lymphoma, and myeloma are projected to cause the deaths of approximately 57,380 people in the US in 2023. This equates to roughly 157 individuals per day or more than six deaths every hour from blood cancer. Thus, the increasing prevalence of hematological disorders is a driving force behind the graft versus host disease (GVHD) treatment market.

Key players in the GVHD treatment market are actively developing advanced drugs and seeking regulatory approval to gain a competitive edge. Product approvals play a crucial role in ensuring that healthcare products meet the necessary standards for safety, efficacy, and quality before they are made available to patients. For instance, in March 2023, Incyte Corporation, a US-based healthcare company, developed ruxolitinib extended-release (XR) tablets, a JAK1/JAK2 inhibitor, which received approval from the Food and Drug Administration (FDA) for once-daily use in treating specific types of myelofibrosis, polycythemia vera, and graft-versus-host disease (GVHD).

In September 2021, Sanofi, a France-based healthcare company, acquired Kadmon for $1.9 billion, strategically aiming to bolster its general medicines core assets and expand its transplant portfolio by incorporating Rezurock (belumosudil), an FDA-approved treatment for chronic graft-versus-host disease (cGVHD). Kadmon Corporation, based in the US, specializes in offering treatments for Graft Versus Host Disease (GvHD), including Rezurock (belumosudil).

Major companies operating in the graft versus host disease (GVHD) treatment market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Sanofi SA, Novartis AG, Bristol Myers Squibb, AstraZeneca, Abbott Laboratories, GlaxoSmithKline plc, Eli Lilly And Company, Novo Nordisk A/S, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Merck KGaA, Teva Pharmaceutical Industries Ltd., Biogen Inc., Astellas Pharma Inc., Jazz Pharmaceuticals plc, Allergan plc, Incyte Corporation, Mallinckrodt Pharmaceuticals, Genzyme Corporation, Kiadis Pharma, Neovii Pharmaceuticals AG, ElsaLys Biotech SA, Mesoblast Ltd., Soligenix

North America was the largest region in the graft versus host disease (GVHD) treatment market in 2023. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the graft versus host disease (GVHD) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the graft versus host disease (GVHD) treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The graft versus host disease (GVHD) treatment market includes revenues earned by entities by immunosuppressive medications, clinical trials, specialized therapies and stem cell transplantation. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Graft Versus Host Disease (GvHD) Treatment Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on graft versus host disease (GvHD) treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
Measure the impact of high global inflation on market growth.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for graft versus host disease (GvHD) treatment? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The graft versus host disease (GvHD) treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of COVID-19 on supply chains and consumption patterns.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Product Type: Corticosteroids; Monoclonal Antibodies; Immunosuppressants; Others
2) By Disease Type: Acute GvHD; Prophylaxis GvHD; Chronic GvHD
3) By End User: Hospitals Pharmacies; Retail Pharmacies; Online Pharmacies
Companies Mentioned: Pfizer Inc.; Johnson & Johnson Services Inc.; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; Sanofi SA
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r18145

1. Executive Summary

2. Graft Versus Host Disease (GvHD) Treatment Market Characteristics

3. Graft Versus Host Disease (GvHD) Treatment Market Trends And Strategies

4. Graft Versus Host Disease (GvHD) Treatment Market - Macro Economic Scenario

4.1. Impact Of High Inflation On The Market
4.2. Ukraine-Russia War Impact On The Market
4.3. COVID-19 Impact On The Market

5. Global Graft Versus Host Disease (GvHD) Treatment Market Size and Growth

5.1. Global Graft Versus Host Disease (GvHD) Treatment Market Drivers and Restraints
- 5.1.1. Drivers Of The Market
- 5.1.2. Restraints Of The Market
5.2. Global Graft Versus Host Disease (GvHD) Treatment Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
5.3. Global Graft Versus Host Disease (GvHD) Treatment Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Graft Versus Host Disease (GvHD) Treatment Market Segmentation

6.1. Global Graft Versus Host Disease (GvHD) Treatment Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Corticosteroids
Monoclonal Antibodies
Immunosuppressants
Others
6.2. Global Graft Versus Host Disease (GvHD) Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Acute GvHD
Prophylaxis GvHD
Chronic GvHD
6.3. Global Graft Versus Host Disease (GvHD) Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies

7. Graft Versus Host Disease (GvHD) Treatment Market Regional And Country Analysis

7.1. Global Graft Versus Host Disease (GvHD) Treatment Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Graft Versus Host Disease (GvHD) Treatment Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Graft Versus Host Disease (GvHD) Treatment Market

8.1. Asia-Pacific Graft Versus Host Disease (GvHD) Treatment Market Overview
Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Graft Versus Host Disease (GvHD) Treatment Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Graft Versus Host Disease (GvHD) Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Graft Versus Host Disease (GvHD) Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Graft Versus Host Disease (GvHD) Treatment Market

9.1. China Graft Versus Host Disease (GvHD) Treatment Market Overview
9.2. China Graft Versus Host Disease (GvHD) Treatment Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Graft Versus Host Disease (GvHD) Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Graft Versus Host Disease (GvHD) Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Graft Versus Host Disease (GvHD) Treatment Market

10.1. India Graft Versus Host Disease (GvHD) Treatment Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Graft Versus Host Disease (GvHD) Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Graft Versus Host Disease (GvHD) Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Graft Versus Host Disease (GvHD) Treatment Market

11.1. Japan Graft Versus Host Disease (GvHD) Treatment Market Overview
11.2. Japan Graft Versus Host Disease (GvHD) Treatment Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Graft Versus Host Disease (GvHD) Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.4. Japan Graft Versus Host Disease (GvHD) Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Graft Versus Host Disease (GvHD) Treatment Market

12.1. Australia Graft Versus Host Disease (GvHD) Treatment Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Graft Versus Host Disease (GvHD) Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Graft Versus Host Disease (GvHD) Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Graft Versus Host Disease (GvHD) Treatment Market

13.1. Indonesia Graft Versus Host Disease (GvHD) Treatment Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Graft Versus Host Disease (GvHD) Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Graft Versus Host Disease (GvHD) Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Graft Versus Host Disease (GvHD) Treatment Market

14.1. South Korea Graft Versus Host Disease (GvHD) Treatment Market Overview
14.2. South Korea Graft Versus Host Disease (GvHD) Treatment Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Graft Versus Host Disease (GvHD) Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.4. South Korea Graft Versus Host Disease (GvHD) Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Graft Versus Host Disease (GvHD) Treatment Market

15.1. Western Europe Graft Versus Host Disease (GvHD) Treatment Market Overview
15.2. Western Europe Graft Versus Host Disease (GvHD) Treatment Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Graft Versus Host Disease (GvHD) Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Graft Versus Host Disease (GvHD) Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Graft Versus Host Disease (GvHD) Treatment Market

16.1. UK Graft Versus Host Disease (GvHD) Treatment Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Graft Versus Host Disease (GvHD) Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Graft Versus Host Disease (GvHD) Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Graft Versus Host Disease (GvHD) Treatment Market

17.1. Germany Graft Versus Host Disease (GvHD) Treatment Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Graft Versus Host Disease (GvHD) Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Graft Versus Host Disease (GvHD) Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Graft Versus Host Disease (GvHD) Treatment Market

18.1. France Graft Versus Host Disease (GvHD) Treatment Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.2. France Graft Versus Host Disease (GvHD) Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.3. France Graft Versus Host Disease (GvHD) Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Graft Versus Host Disease (GvHD) Treatment Market

19.1. Italy Graft Versus Host Disease (GvHD) Treatment Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.2. Italy Graft Versus Host Disease (GvHD) Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.3. Italy Graft Versus Host Disease (GvHD) Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Graft Versus Host Disease (GvHD) Treatment Market

20.1. Spain Graft Versus Host Disease (GvHD) Treatment Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.2. Spain Graft Versus Host Disease (GvHD) Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.3. Spain Graft Versus Host Disease (GvHD) Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Graft Versus Host Disease (GvHD) Treatment Market

21.1. Eastern Europe Graft Versus Host Disease (GvHD) Treatment Market Overview
21.2. Eastern Europe Graft Versus Host Disease (GvHD) Treatment Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Graft Versus Host Disease (GvHD) Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Graft Versus Host Disease (GvHD) Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Graft Versus Host Disease (GvHD) Treatment Market

22.1. Russia Graft Versus Host Disease (GvHD) Treatment Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Graft Versus Host Disease (GvHD) Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Graft Versus Host Disease (GvHD) Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Graft Versus Host Disease (GvHD) Treatment Market

23.1. North America Graft Versus Host Disease (GvHD) Treatment Market Overview
23.2. North America Graft Versus Host Disease (GvHD) Treatment Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Graft Versus Host Disease (GvHD) Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Graft Versus Host Disease (GvHD) Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Graft Versus Host Disease (GvHD) Treatment Market

24.1. USA Graft Versus Host Disease (GvHD) Treatment Market Overview
24.2. USA Graft Versus Host Disease (GvHD) Treatment Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Graft Versus Host Disease (GvHD) Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Graft Versus Host Disease (GvHD) Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Graft Versus Host Disease (GvHD) Treatment Market

25.1. Canada Graft Versus Host Disease (GvHD) Treatment Market Overview
25.2. Canada Graft Versus Host Disease (GvHD) Treatment Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Graft Versus Host Disease (GvHD) Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Graft Versus Host Disease (GvHD) Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Graft Versus Host Disease (GvHD) Treatment Market

26.1. South America Graft Versus Host Disease (GvHD) Treatment Market Overview
26.2. South America Graft Versus Host Disease (GvHD) Treatment Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Graft Versus Host Disease (GvHD) Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Graft Versus Host Disease (GvHD) Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Graft Versus Host Disease (GvHD) Treatment Market

27.1. Brazil Graft Versus Host Disease (GvHD) Treatment Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Graft Versus Host Disease (GvHD) Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Graft Versus Host Disease (GvHD) Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Graft Versus Host Disease (GvHD) Treatment Market

28.1. Middle East Graft Versus Host Disease (GvHD) Treatment Market Overview
28.2. Middle East Graft Versus Host Disease (GvHD) Treatment Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Graft Versus Host Disease (GvHD) Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Graft Versus Host Disease (GvHD) Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Graft Versus Host Disease (GvHD) Treatment Market

29.1. Africa Graft Versus Host Disease (GvHD) Treatment Market Overview
29.2. Africa Graft Versus Host Disease (GvHD) Treatment Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Graft Versus Host Disease (GvHD) Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Graft Versus Host Disease (GvHD) Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Graft Versus Host Disease (GvHD) Treatment Market Competitive Landscape And Company Profiles

30.1. Graft Versus Host Disease (GvHD) Treatment Market Competitive Landscape
30.2. Graft Versus Host Disease (GvHD) Treatment Market Company Profiles
- 30.2.1. Pfizer Inc.
  - 30.2.1.1. Overview
  - 30.2.1.2. Products and Services
  - 30.2.1.3. Strategy
  - 30.2.1.4. Financial Performance
- 30.2.2. Johnson & Johnson Services Inc.
  - 30.2.2.1. Overview
  - 30.2.2.2. Products and Services
  - 30.2.2.3. Strategy
  - 30.2.2.4. Financial Performance
- 30.2.3. F. Hoffmann-La Roche Ltd.
  - 30.2.3.1. Overview
  - 30.2.3.2. Products and Services
  - 30.2.3.3. Strategy
  - 30.2.3.4. Financial Performance
- 30.2.4. Merck & Co. Inc.
  - 30.2.4.1. Overview
  - 30.2.4.2. Products and Services
  - 30.2.4.3. Strategy
  - 30.2.4.4. Financial Performance
- 30.2.5. Sanofi SA
  - 30.2.5.1. Overview
  - 30.2.5.2. Products and Services
  - 30.2.5.3. Strategy
  - 30.2.5.4. Financial Performance

31. Graft Versus Host Disease (GvHD) Treatment Market Other Major And Innovative Companies

31.1. Novartis AG
31.2. Bristol Myers Squibb
31.3. AstraZeneca
31.4. Abbott Laboratories
31.5. GlaxoSmithKline plc
31.6. Eli Lilly And Company
31.7. Novo Nordisk A/S
31.8. Takeda Pharmaceutical Company Limited
31.9. Gilead Sciences Inc.
31.10. Merck KGaA
31.11. Teva Pharmaceutical Industries Ltd.
31.12. Biogen Inc.
31.13. Astellas Pharma Inc.
31.14. Jazz Pharmaceuticals plc
31.15. Allergan plc

32. Global Graft Versus Host Disease (GvHD) Treatment Market Competitive Benchmarking

33. Global Graft Versus Host Disease (GvHD) Treatment Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Graft Versus Host Disease (GvHD) Treatment Market

35. Graft Versus Host Disease (GvHD) Treatment Market Future Outlook and Potential Analysis

35.1 Graft Versus Host Disease (GvHD) Treatment Market In 2028 - Countries Offering Most New Opportunities
35.2 Graft Versus Host Disease (GvHD) Treatment Market In 2028 - Segments Offering Most New Opportunities
35.3 Graft Versus Host Disease (GvHD) Treatment Market In 2028 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer